AbbVie announced that the FDA has granted Orphan Drug designation to ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, being evaluated for patients with glioblastoma multiforme.
ABT-414 is designed to be stable in the bloodstream and only release the potent cytotoxic agent once inside targeted cancer cells.
RELATED: Expanded Use of Imbruvica Approved
ABT-414 is currently under investigation for the treatment of patients with various cancer and tumor types. AbbVie has also initiated clinical trials evaluating the use of ABT-414 for the treatment of patients with squamous cell tumors.
For more information call (800) 633-9110 or visit AbbVie.com.
